Glaxo Slips 3% On Weak EU Pricing
GlaxoSmithKline shares slipped 3% on weak pricing in Europe, which overshadowed the pharmaceutical companyÂ’s promise to return to sales growth in 2012. Shares of Glaxo (GSK), the United KingdomÂ’s largest drug maker were off $1.42 to $45.76 in afternoon trading. The company said first-quarter net profit was down 13% year over year, to 1.33 billion [...]

GlaxoSmithKline shares slipped 3% on weak pricing in Europe, which overshadowed the pharmaceutical company’s promise to return to sales growth in 2012.

Shares of Glaxo (GSK), the United Kingdom’s largest drug maker were off $1.42 to $45.76 in afternoon trading.

The company said first-quarter net profit was down 13% year over year, to 1.33 billion pounds ($2.15 billion); the year-ago period included one-time gains from the sale of Glaxo’s stake in Quest Diagnostics. Sales rose just less than 1%, to 6.64 billion pounds, lower than the 6.79 billion analysts were expecting.

Sales were strong in the United States, and Glaxo said it will continue to buy back shares. It also defended its hostile bid for Human Genome Sciences (HGSI), saying Glaxo’s existing interests make it the compelling owner.

The company said a prepared release that:

“We remain mindful of the challenges we face given the current global political and economic environment, particularly in relation to pricing on our more established products. However, we also continue to see attractive growth opportunities across our businesses” including positive 2012 pipeline data “for five Phase III assets for the treatment of HIV, cancer, diabetes and asthma.”

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here